Cilnidipine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cilnidipine
Accession Number
DB09232
Type
Small Molecule
Groups
Approved
Description

Cilnidipine (INN) is a calcium channel blocker. Cilnidipine is the novel calcium antagonist accompanied with L-type and N-type calcium channel blocking function. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved to come into market for the first time and used for high blood pressure treatment in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium antagonists. Cilnidipine is approved for use in Japan, China,India, Korea and some European countries.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Atelec / Cilogard
Categories
UNII
97T5AZ1JIP
CAS number
132203-70-4
Weight
Average: 492.528
Monoisotopic: 492.18965125
Chemical Formula
C27H28N2O7
InChI Key
KJEBULYHNRNJTE-DHZHZOJOSA-N
InChI
InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+
IUPAC Name
3-(2-methoxyethyl) 5-(2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Cilnidipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Cilnidipine.Vet Approved
AcebutololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Acebutolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Cilnidipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Cilnidipine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Cilnidipine.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Amlodipine.Approved
AmobarbitalThe metabolism of Cilnidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Cilnidipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cilnidipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Amyl Nitrite.Approved
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Cilnidipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Cilnidipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Cilnidipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cilnidipine.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cilnidipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Cilnidipine.Approved
AtenololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Atosiban.Approved
Atracurium besylateCilnidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Azilsartan medoxomil.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Cilnidipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Cilnidipine.Experimental
BarbitalThe metabolism of Cilnidipine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Cilnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Bendroflumethiazide.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Cilnidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Cilnidipine.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Betaxolol.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Cilnidipine.Approved
BisoprololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Cilnidipine.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Cilnidipine.Experimental
BretyliumThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cilnidipine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Cilnidipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Cilnidipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cilnidipine.Approved, Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Cilnidipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Cilnidipine.Approved
CalciumThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium CitrateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Phosphate.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Candesartan.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Cilnidipine.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Cilnidipine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Cilnidipine.Approved
CarbomycinThe metabolism of Cilnidipine can be decreased when combined with Carbomycin.Vet Approved
CarteololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Carteolol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Cilnidipine.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Cilnidipine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Cilnidipine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cilnidipine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Chlorthalidone.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Cilnidipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Cilazapril.Approved
CimetidineThe serum concentration of Cilnidipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Cilnidipine can be decreased when combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clonidine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cilnidipine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Cilnidipine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Cilnidipine.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cilnidipine.Approved, Investigational, Vet Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Cilnidipine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Dexmedetomidine.Approved, Vet Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Cilnidipine.Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Diclofenamide.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Dipyridamole.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Cilnidipine.Approved
DuloxetineCilnidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Cilnidipine.Approved
EfavirenzThe serum concentration of Cilnidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Cilnidipine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Eprosartan.Approved
ErythromycinThe metabolism of Cilnidipine can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Etacrynic acid.Approved
FelodipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fenoldopam.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Cilnidipine.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Cilnidipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Cilnidipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Cilnidipine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fluvastatin.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Cilnidipine.Approved
FurosemideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Furosemide.Approved, Vet Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Cilnidipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Cilnidipine.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Guanfacine.Approved, Investigational
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Cilnidipine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Cilnidipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Halothane.Approved, Vet Approved
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Cilnidipine.Approved
HexobarbitalThe metabolism of Cilnidipine can be increased when combined with Hexobarbital.Approved
HydralazineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Hydroflumethiazide.Approved
IloprostThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Indapamide.Approved
IndoraminIndoramin may increase the hypotensive activities of Cilnidipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isocarboxazid.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Cilnidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isradipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Cilnidipine.Approved, Investigational
JosamycinThe metabolism of Cilnidipine can be decreased when combined with Josamycin.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Cilnidipine.Approved, Investigational
KitasamycinThe metabolism of Cilnidipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Cilnidipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Levobupivacaine.Approved
LevodopaCilnidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lisinopril.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Losartan.Approved
LovastatinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Lovastatin.Approved, Investigational
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium Sulfate.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Mannitol.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Mecamylamine.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Cilnidipine.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Methazolamide.Approved
MethohexitalThe metabolism of Cilnidipine can be increased when combined with Methohexital.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Methyldopa.Approved
MethylphenobarbitalThe metabolism of Cilnidipine can be increased when combined with Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Metoprolol.Approved, Investigational
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Cilnidipine.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Cilnidipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Cilnidipine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Cilnidipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Minoxidil.Approved
MivacuriumCilnidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Moexipril.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Cilnidipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Moxonidine.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Cilnidipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nadolol.Approved
NafcillinThe metabolism of Cilnidipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Cilnidipine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Cilnidipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Cilnidipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nifedipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Cilnidipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Cilnidipine.Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideCilnidipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Cilnidipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Cilnidipine.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Obinutuzumab.Approved
OleandomycinThe metabolism of Cilnidipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Olmesartan.Approved, Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Cilnidipine.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Cilnidipine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Cilnidipine.Investigational
PapaverineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Papaverine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Cilnidipine.Approved
PentobarbitalThe metabolism of Cilnidipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Cilnidipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cilnidipine.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pipamperone.Approved
PitavastatinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pitavastatin.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Cilnidipine.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pramipexole.Approved, Investigational
PravastatinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Cilnidipine.Approved
PrimidoneThe metabolism of Cilnidipine can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Propranolol.Approved, Investigational
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Cilnidipine.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Quinapril.Approved, Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Cilnidipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Ramipril.Approved
RapacuroniumCilnidipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Reserpine.Approved
RifabutinThe serum concentration of Cilnidipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Cilnidipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Cilnidipine can be decreased when it is combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Riociguat.Approved
RisperidoneCilnidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Ropivacaine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Rosuvastatin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sacubitril.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Cilnidipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Cilnidipine.Approved, Vet Approved
SecobarbitalThe metabolism of Cilnidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Selegiline.Approved, Investigational, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Cilnidipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sevoflurane.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Cilnidipine.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Cilnidipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cilnidipine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sodium Nitrite.Approved
SolithromycinThe metabolism of Cilnidipine can be decreased when combined with Solithromycin.Investigational
SotalolThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Cilnidipine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Cilnidipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Cilnidipine.Approved
TelithromycinThe metabolism of Cilnidipine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Telmisartan.Approved, Investigational
TerazosinTerazosin may increase the hypotensive activities of Cilnidipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Cilnidipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Cilnidipine.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe metabolism of Cilnidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Cilnidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Thioridazine.Withdrawn
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Cilnidipine.Approved
TimololThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Timolol.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Cilnidipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tolcapone.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Cilnidipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Cilnidipine.Approved, Vet Approved
TorasemideThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Triamterene.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Cilnidipine.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Cilnidipine.Approved, Investigational
TylosinThe metabolism of Cilnidipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Ubidecarenone.Experimental
UrapidilUrapidil may increase the hypotensive activities of Cilnidipine.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Valsartan.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Verapamil.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Cilnidipine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
KEGG Drug
D01173
PubChem Compound
5282138
PubChem Substance
310265136
ChemSpider
4445338
ChEBI
31399
ChEMBL
CHEMBL452076
Wikipedia
Cilnidipine
ATC Codes
C08CA14 — Cilnidipine
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHypertensive1
2Unknown StatusTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3CompletedTreatmentHypertensive / Strokes1
4CompletedTreatmentHypertensive / Metabolic Syndromes1
4Unknown StatusTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000566 mg/mLALOGPS
logP4.39ALOGPS
logP4.1ChemAxon
logS-5.9ALOGPS
pKa (Strongest Acidic)19.46ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area117 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity137.14 m3·mol-1ChemAxon
Polarizability51.97 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0012490000-56c247612ff7c5dfa146
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-2915100000-4bb1d47549a538dcee61

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Styrenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Dialkyl ethers
show 8 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Styrene / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dihydropyridine (CHEBI:31399)

Drug created on October 23, 2015 10:20 / Updated on October 02, 2017 06:14